SCHEMBL3358375

SCHEMBL3358375

CCN1C(=O)CS/C1=C(/C#N)C(=O)NCC(F)F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.46
▸ MAPT P10636 4/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ LMNA P02545 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ HSD17B10 Q99714 3/20 0.43
▸ DHODH Q02127 8/20 0.38
▸ PLK1 P53350 1/20 0.38
▸ L3MBTL1 Q9Y468 3/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ THRB P10828 2/20 0.31
▸ USP2 O75604 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13488668 1.00 ALDH1A1 (0.46) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL13488664 0.86 ALDH1A1 (0.49) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL3358918 0.86 ALDH1A1 (0.49) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL13488667 0.85 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL3358942 0.85 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL3354063 0.84 ALDH1A1 (0.46) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL3354225 0.83 MEN1 (0.46) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL13488665 0.83 MEN1 (0.46) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL13488666 0.83 ALDH1A1 (0.47) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL13489800 0.83 ALDH1A1 (0.47) ALDH1A1MAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048891-A1 METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG SCHULZE KLAUSE 2010-02-25 — — US disclosed
EP-2141163-A1 Substituted thiazolidinones, their production and utilisation as medicine Bayer Schering Pharma AG (DE) 2010-01-06 — — EP disclosed
US-20070010566-A1 Thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-11 — — US disclosed
US-20070010566-A1 Thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-11 — — US disclosed
US-20070010565-A1 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-11 — — US disclosed
US-20070010565-A1 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048891-A1 METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG PLK2, PDXK, PLK4 ALDH1A1 1600/4885MAPT 705/4885MEN1 3222/4885
US-20070010566-A1 Thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents PLK4, PLK2, PLK3 ALDH1A1 1627/4885MAPT 225/4885MEN1 3128/4885
US-20070010565-A1 New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents PLK4, PLK2, PLK3 ALDH1A1 1600/4885MAPT 796/4885MEN1 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback